News Archive
Pictor, Inc. Partners with Protean BioDiagnostics to Advance Autoimmune and Chronic Infectious Disease Diagnostics
San Diego, California: Pictor, Inc., has entered into a collaboration agreement with Protean BioDiagnostics to address the unmet needs of autoimmune and chronic infectious diseases. Under the agreement, Protean BioDiagnostics will develop and validate the Pictor PictHealthTM Extractable Nuclear Antigen (ENA) IgG Multiplex ELISA, which identifies antibodies associated with autoimmune diseases to help diagnose and […]
Disrupting a market, not creating one
Article from the “CAFFEINE” – The daily for New Zealand’s Startups What kiwi founders could learn from the turnaround at Auckland biotech company Pictor under new CEO Jamie Platt. Click here for the full article
Pictor launches novel best-in-class M. bovis test as new outbreak hits NZ
Pictor Limited, a New Zealand based biotechnology company, has launched a ground-breaking M. bovis test for global markets. Launch of the Pictor PictVet™ Mycoplasma bovis Multiplex ELISA Kit comes at a time when new cases of M. bovis have been found in Canterbury. Pictor Managing Director, Dr. Jamie Platt says: “After several years in development […]
Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test
$5 million raise to accelerate global market development and product development AUCKLAND, New Zealand, December 05, 2022— Pictor, a global leader in immunodiagnostics, today announced a funding round to help accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios. This […]
Pictor and Rako Science bring improved access to COVID-19 antibody testing for New Zealand with technology from Tasso
November 16, 2022 12pm NZDT AUCKLAND, New Zealand — Pictor, a global leader in immunodiagnostics, today announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test will soon be available in New Zealand. Rako Science will utilize its national network by collecting blood samples with a device from Tasso, Inc., and undertake testing […]
Biotech Firm Tackling COVID-19 and M.bovis Announces Successful Development of Rapid, Accurate Johne’s Disease Assay
Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production. “The PictArray™ MAP assay would be a positive addition to national control programs to help in the eradication of Johne’s disease from the dairy industry,” says Pictor’s Director of Research and Development, Dr. Natasha Gordon, who will be presenting at a Johne’s disease conference this week in Dublin, Ireland.
Bolstered By Investment, Pictor Partners with Mobility Health to Offer PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster
Following a new investment of $6.1 million (NZD $8.8 million), biotech company Pictor today announced a partnership with U.S. laboratory service provider Mobility Health, launching a new antibody test as an important advance in COVID-19 monitoring and treatment. The investment, led by former Morrison & Co CEO Marko Bogoievski, and specialist growth investor K One W One Ltd. (K1W1), will support market and product development of the new antibody test and other Pictor in vitro diagnostics.